Cancer-Killing virus trial launches for melanoma that spread to brain
NCT ID NCT07444606
First seen Mar 18, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This early-phase trial tests a virus called DNX-2401, designed to infect and destroy melanoma cells in the brain and body. About 50 adults with stage IV melanoma will receive injections to find the safest dose and number of treatments. The main goal is to check for side effects, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNX-2401 (an oncolytic virus that infects and kills cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for melanoma that has spread to the brain and other parts of the body.
What could go wrong
This is a very early phase 1 trial with only 50 participants, focused on safety and dosing. It is not yet known if DNX-2401 will shrink tumors or improve survival, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.